Skip to content

Teriparatide (PTH 1-34) studies: 484 papers with results

Page 5 of 10

  1. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study.

    Piemonte S · Calcified tissue international · 2009

    Non-randomized trial · 12 results

  2. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.

    Mitsopoulos E · American journal of nephrology · 2012

    Non-randomized trial · 2 results

  3. Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.

    Slovik DM · The Journal of clinical investigation · 1981

    Non-randomized trial · 14 results

  4. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.

    Miki T · Journal of bone and mineral metabolism · 2004

    Non-randomized trial · 8 results

  5. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.

    Gafni RI · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012

    Non-randomized trial · 16 results

  6. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.

    Lindsay R · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2006

    Non-randomized trial · 5 results

  7. Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis.

    Daddona PE · Pharmaceutical research · 2011

    Non-randomized trial · 7 results

  8. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

    Miller PD · The Journal of clinical endocrinology and metabolism · 2008

    Non-randomized trial · 6 results

  9. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis.

    Satterwhite J · Calcified tissue international · 2010

    Non-randomized trial · 7 results

  10. Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice.

    Yu M · EMBO reports · 2018

    Non-randomized trial · 5 results

  11. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.

    Blumsohn A · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2011

    Non-randomized trial · 5 results

  12. Effects of teriparatide retreatment in osteoporotic men and women.

    Finkelstein JS · The Journal of clinical endocrinology and metabolism · 2009

    Non-randomized trial · 5 results

  13. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study.

    Jung J · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017

    Non-randomized trial · 6 results

  14. The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture.

    Tsuchie H · Journal of bone and mineral metabolism · 2016

    Non-randomized trial · 9 results

  15. Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.

    Sugimoto T · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014

    Non-randomized trial · 12 results

  16. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

    Dobnig H · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2009

    Non-randomized trial · 6 results

  17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

    Gallagher JC · Bone · 2006

    Non-randomized trial · 9 results

  18. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.

    Prevrhal S · Current medical research and opinion · 2009

    Non-randomized trial · 4 results

  19. Teriparatide Administration Increases Periprosthetic Bone Mineral Density After Total Knee Arthroplasty: A Prospective Study.

    Suzuki T · The Journal of arthroplasty · 2018

    Non-randomized trial · 6 results

  20. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.

    Panico A · Medical science monitor : international medical journal of experimental and clinical research · 2011

    Non-randomized trial · 6 results

  21. Teriparatide and denosumab combination therapy and skeletal metabolism.

    Idolazzi L · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016

    Non-randomized trial · 4 results

  22. Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.

    Dempster DW · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016

    Non-randomized trial · 8 results

  23. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

    Nakano T · Journal of bone and mineral metabolism · 2014

    Non-randomized trial · 10 results

  24. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment.

    Watts NB · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2009

    Non-randomized trial · 5 results

  25. Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis.

    Pearson RG · Pharmaceutics · 2019

    Non-randomized trial · 6 results

  26. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.

    Deng J · Medicine · 2018

    Non-randomized trial · 13 results

  27. Treatment responses with once-weekly teriparatide therapy for osteoporosis.

    Shiraki M · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016

    Non-randomized trial · 4 results

  28. Teriparatide treatment in severe osteoporosis - a controlled 10-year follow-up study.

    Kontogeorgos G · BMC musculoskeletal disorders · 2022

    Non-randomized trial · 5 results

  29. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.

    Sumida K · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016

    Observational study · 11 results

  30. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

    Miller PD · Bone · 2019

    Observational study · 15 results

  31. Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS).

    Wen MT · Expert opinion on drug safety · 2025

    Observational study · 20 results

  32. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years.

    Gilsenan A · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018

    Observational study · 1 result

  33. Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.

    Tabatabai L · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025

    Observational study · 10 results

  34. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.

    Cosman F · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022

    Observational study · 8 results

  35. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.

    Langdahl BL · Bone · 2018

    Observational study · 9 results

  36. Teriparatide in patients with osteoporosis and type 2 diabetes.

    Schwartz AV · Bone · 2016

    Observational study · 4 results

  37. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.

    Nishikawa A · Clinical interventions in aging · 2016

    Observational study · 16 results

  38. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).

    Langdahl BL · Calcified tissue international · 2016

    Observational study · 5 results

  39. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.

    Prince R · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2005

    Observational study · 13 results

  40. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.

    Gilsenan A · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021

    Observational study · 2 results

  41. Persistence with teriparatide in patients with osteoporosis: the UK experience.

    Arden NK · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2006

    Observational study · 3 results

  42. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.

    Crans GG · Arthritis and rheumatism · 2004

    Observational study · 1 result

  43. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.

    Obermayer-Pietsch BM · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2008

    Observational study · 12 results

  44. Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling.

    Winzenrieth R · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021

    Observational study · 16 results

  45. SUN-385 Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-Based 3d Modeling

    Winzenrieth R · Journal of the Endocrine Society · 2020

    Observational study · 18 results

  46. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.

    Eastell R · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019

    Observational study · 8 results

  47. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

    Kaufman JM · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2005

    Observational study · 7 results

  48. Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy.

    Xie Z · Clinical interventions in aging · 2019

    Observational study · 4 results

  49. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.

    Lyu H · The Journal of clinical endocrinology and metabolism · 2019

    Observational study · 5 results

  50. Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures.

    Huang TW · Medicine · 2016

    Observational study · 6 results

How PepBank reports evidence